News
Zacks Investment Research on MSN19h
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...
Zacks Investment Research on MSN23h
Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength?BioMarin Pharmaceutical BMRN shares ended the last trading session 6.3% higher at $59.43. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time ...
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating ...
Korea Investment CORP grew its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 362.5% ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Recursion Pharmaceuticals (RXRX – Research ...
Zacks.com on MSN19h
What Makes BioMarin (BMRN) a New Buy StockBioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback